ReviewActa clinica Croatica2024
EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS INDUCED BY MONTELUKAST.
Review in Acta clinica Croatica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Article
- Dual pathogenesis and treatment approaches for eosinophilic granulomatosis with polyangiitis: a comprehensive review.Reumatologia · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leukotriene receptor antagonists are a class of drugs used in maintenance therapy of asthma. Among the adverse effects induced by them, particularly by montelukast, is eosinophilic granulomatosis with polyangiitis (EGPA), which manifests as a form of vasculitis co-occurring with severe asthma and eosinophilia. Our aim was to point to the importance of this particular diagnosis by analyzing the published cases of montelukast induced EGPA and to analyze them in order to identify if this form of EGPA presented some specific characteristics. Leukotriene receptor antagonist induced EGPA is a frequent adverse event compared to EGPA induced by other drugs, and specialists should be aware of it. We observed that more than half of patients were female. Montelukast induced EGPA occurred after a variable period of time. The most common clinical manifestation was neuropathy and most of the patients had a good outcome after immunosuppressant treatment. The present diagnosis should be considered by physicians when patients are prescribed montelukast followed by worsening of symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.